KR20070085340A - 폐쇄성 동맥 질환용의 아릴 설폰아미드 주변 치환된바이사이클릭 화합물 - Google Patents
폐쇄성 동맥 질환용의 아릴 설폰아미드 주변 치환된바이사이클릭 화합물 Download PDFInfo
- Publication number
- KR20070085340A KR20070085340A KR1020077010839A KR20077010839A KR20070085340A KR 20070085340 A KR20070085340 A KR 20070085340A KR 1020077010839 A KR1020077010839 A KR 1020077010839A KR 20077010839 A KR20077010839 A KR 20077010839A KR 20070085340 A KR20070085340 A KR 20070085340A
- Authority
- KR
- South Korea
- Prior art keywords
- substituted
- mmol
- lower alkyl
- equiv
- give
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 0 Cc1cccc2c1[n](C)cc2* Chemical compound Cc1cccc2c1[n](C)cc2* 0.000 description 2
- WHPCPKNZBUEWBS-UHFFFAOYSA-N CC(C)c1c[n](C)c2c1cccc2C Chemical compound CC(C)c1c[n](C)c2c1cccc2C WHPCPKNZBUEWBS-UHFFFAOYSA-N 0.000 description 1
- LZWPRWKXTVAMTJ-UHFFFAOYSA-N CC(C1C(C)=NNC11)N(C)C1=O Chemical compound CC(C1C(C)=NNC11)N(C)C1=O LZWPRWKXTVAMTJ-UHFFFAOYSA-N 0.000 description 1
- WPXVXALDGRPBJJ-UHFFFAOYSA-N CC(c(c(C)ccc1)c1N1)(C1=O)F Chemical compound CC(c(c(C)ccc1)c1N1)(C1=O)F WPXVXALDGRPBJJ-UHFFFAOYSA-N 0.000 description 1
- CRGREZDPYNLXTC-UHFFFAOYSA-N CC(c(cc(cc1C)F)c1N1C)C1=O Chemical compound CC(c(cc(cc1C)F)c1N1C)C1=O CRGREZDPYNLXTC-UHFFFAOYSA-N 0.000 description 1
- QXSGPVUSUQURNO-UHFFFAOYSA-N CC(c(cccc1C)c1N1C)C1=O Chemical compound CC(c(cccc1C)c1N1C)C1=O QXSGPVUSUQURNO-UHFFFAOYSA-N 0.000 description 1
- PHIDJIUDVLROLI-UHFFFAOYSA-N CC(c1c[n](C)c2c1cccc2C)=O Chemical compound CC(c1c[n](C)c2c1cccc2C)=O PHIDJIUDVLROLI-UHFFFAOYSA-N 0.000 description 1
- PEYNVVVZLHKYNA-UHFFFAOYSA-N CC1(CC(N2C)=O)C2=C(C)CCC1 Chemical compound CC1(CC(N2C)=O)C2=C(C)CCC1 PEYNVVVZLHKYNA-UHFFFAOYSA-N 0.000 description 1
- ORFNTSLTIIPWKB-UHFFFAOYSA-N C[n]1c2cccc(-c(cc3)ccc3NS(c([s]3)cc(Cl)c3Cl)(=O)=O)c2c(Cc2cc(cccc3)c3cc2)c1 Chemical compound C[n]1c2cccc(-c(cc3)ccc3NS(c([s]3)cc(Cl)c3Cl)(=O)=O)c2c(Cc2cc(cccc3)c3cc2)c1 ORFNTSLTIIPWKB-UHFFFAOYSA-N 0.000 description 1
- JULBNUYMIXPZHD-UHFFFAOYSA-N C[n]1c2cccc(-c3cc(NS(c([s]4)cc(Cl)c4Cl)(=O)=O)c[nH]3)c2c(Cc2cc(cccc3)c3cc2)c1 Chemical compound C[n]1c2cccc(-c3cc(NS(c([s]4)cc(Cl)c4Cl)(=O)=O)c[nH]3)c2c(Cc2cc(cccc3)c3cc2)c1 JULBNUYMIXPZHD-UHFFFAOYSA-N 0.000 description 1
- XZMMSGGIVXOCOH-UHFFFAOYSA-N C[n]1c2cccc(-c3cccc(NS(c([s]4)cc(Cl)c4Cl)(=O)=O)c3)c2c(Cc2cc(cccc3)c3cc2)c1 Chemical compound C[n]1c2cccc(-c3cccc(NS(c([s]4)cc(Cl)c4Cl)(=O)=O)c3)c2c(Cc2cc(cccc3)c3cc2)c1 XZMMSGGIVXOCOH-UHFFFAOYSA-N 0.000 description 1
- APDXIWFSRCVTMJ-UHFFFAOYSA-N C[n]1c2cccc(-c3nnc(NS(c([s]4)cc(Cl)c4Cl)(=O)=O)[o]3)c2c(Cc2cc(cccc3)c3cc2)c1 Chemical compound C[n]1c2cccc(-c3nnc(NS(c([s]4)cc(Cl)c4Cl)(=O)=O)[o]3)c2c(Cc2cc(cccc3)c3cc2)c1 APDXIWFSRCVTMJ-UHFFFAOYSA-N 0.000 description 1
- RZTIAKZTSHAJEI-UHFFFAOYSA-N Cc(cccc1C23OCCO2)c1N(C)C3=O Chemical compound Cc(cccc1C23OCCO2)c1N(C)C3=O RZTIAKZTSHAJEI-UHFFFAOYSA-N 0.000 description 1
- UTYMKMPQDZCNFE-UHFFFAOYSA-N Cc(cccc1C23SCCN2)c1N(C)C3=O Chemical compound Cc(cccc1C23SCCN2)c1N(C)C3=O UTYMKMPQDZCNFE-UHFFFAOYSA-N 0.000 description 1
- ULQRIOFGHSHNEV-UHFFFAOYSA-N Cc(cccc1O2)c1N(C)C2=O Chemical compound Cc(cccc1O2)c1N(C)C2=O ULQRIOFGHSHNEV-UHFFFAOYSA-N 0.000 description 1
- JBLQVLLTGGSFKT-UHFFFAOYSA-N Cc1c([n](C)cc2)[n]2nc1 Chemical compound Cc1c([n](C)cc2)[n]2nc1 JBLQVLLTGGSFKT-UHFFFAOYSA-N 0.000 description 1
- SEIWGTKMFAPUGC-UHFFFAOYSA-N Cc1c2[n](C)ccc2cc(F)c1 Chemical compound Cc1c2[n](C)ccc2cc(F)c1 SEIWGTKMFAPUGC-UHFFFAOYSA-N 0.000 description 1
- SOKQROSLNCMNNP-UHFFFAOYSA-N Cc1c2[n](C)cnc2ccc1 Chemical compound Cc1c2[n](C)cnc2ccc1 SOKQROSLNCMNNP-UHFFFAOYSA-N 0.000 description 1
- KATIOHPPAYHCKE-UHFFFAOYSA-N Cc1c[n](C)c(c(C)c2)c1cc2F Chemical compound Cc1c[n](C)c(c(C)c2)c1cc2F KATIOHPPAYHCKE-UHFFFAOYSA-N 0.000 description 1
- IUEXCOWAYRHFEP-UHFFFAOYSA-N Cc1c[o]c2c1c(C)ccc2 Chemical compound Cc1c[o]c2c1c(C)ccc2 IUEXCOWAYRHFEP-UHFFFAOYSA-N 0.000 description 1
- SHFYWDWZSJFCEV-UHFFFAOYSA-N Cc1cccc(C2(C(F)(F)F)O)c1N(C)C2=O Chemical compound Cc1cccc(C2(C(F)(F)F)O)c1N(C)C2=O SHFYWDWZSJFCEV-UHFFFAOYSA-N 0.000 description 1
- JGOPTKIFPPFPNW-UHFFFAOYSA-N Cc1cccc(C2)c1N(C)C2=O Chemical compound Cc1cccc(C2)c1N(C)C2=O JGOPTKIFPPFPNW-UHFFFAOYSA-N 0.000 description 1
- UVIBNQOZLYICJH-UHFFFAOYSA-N Cc1cccc(C2=O)c1N(C)C2=O Chemical compound Cc1cccc(C2=O)c1N(C)C2=O UVIBNQOZLYICJH-UHFFFAOYSA-N 0.000 description 1
- FWIFXCARKJCTGL-UHFFFAOYSA-N Cc1cccc2c1[n](C)cc2C=O Chemical compound Cc1cccc2c1[n](C)cc2C=O FWIFXCARKJCTGL-UHFFFAOYSA-N 0.000 description 1
- ODAKCTALIIAAAU-UHFFFAOYSA-N Cc1cccc2c1[n](C)cc2CO Chemical compound Cc1cccc2c1[n](C)cc2CO ODAKCTALIIAAAU-UHFFFAOYSA-N 0.000 description 1
- MLLAKYWBHVJPMX-UHFFFAOYSA-N Cc1cccc2c1[n](C)cc2COC Chemical compound Cc1cccc2c1[n](C)cc2COC MLLAKYWBHVJPMX-UHFFFAOYSA-N 0.000 description 1
- DSMGIIYQJWEEJG-UHFFFAOYSA-N Cc1cnc2[s]cc(C)[n]12 Chemical compound Cc1cnc2[s]cc(C)[n]12 DSMGIIYQJWEEJG-UHFFFAOYSA-N 0.000 description 1
- RTSCAHNREVQUJN-UHFFFAOYSA-N Cc1n[n](C)c2c1c(C)ccc2 Chemical compound Cc1n[n](C)c2c1c(C)ccc2 RTSCAHNREVQUJN-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Indole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61820204P | 2004-10-12 | 2004-10-12 | |
| US60/618,202 | 2004-10-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20070085340A true KR20070085340A (ko) | 2007-08-27 |
Family
ID=35677621
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020077010839A Ceased KR20070085340A (ko) | 2004-10-12 | 2005-10-11 | 폐쇄성 동맥 질환용의 아릴 설폰아미드 주변 치환된바이사이클릭 화합물 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20060142348A1 (https=) |
| EP (1) | EP1812426B1 (https=) |
| JP (1) | JP2008515980A (https=) |
| KR (1) | KR20070085340A (https=) |
| CN (1) | CN101076529A (https=) |
| AT (1) | ATE512144T1 (https=) |
| AU (1) | AU2005295902A1 (https=) |
| BR (1) | BRPI0517417A (https=) |
| CA (1) | CA2583710A1 (https=) |
| IL (1) | IL182489A0 (https=) |
| MX (1) | MX2007004526A (https=) |
| NO (1) | NO20072269L (https=) |
| NZ (1) | NZ554493A (https=) |
| RU (1) | RU2407736C2 (https=) |
| SG (1) | SG156637A1 (https=) |
| WO (1) | WO2006044405A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GT200500185A (es) * | 2004-08-09 | 2006-04-10 | Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos | |
| ES2524922T3 (es) | 2005-05-10 | 2014-12-15 | Intermune, Inc. | Derivados de piridona para modular el sistema de proteína cinasa activada por estrés |
| US20090163586A1 (en) | 2007-12-20 | 2009-06-25 | Astrazeneca Ab | Bis-(Sulfonylamino) Derivatives in Therapy 205 |
| CA2726588C (en) | 2008-06-03 | 2019-04-16 | Karl Kossen | Compounds and methods for treating inflammatory and fibrotic disorders |
| FR2938538B1 (fr) * | 2008-11-17 | 2011-08-05 | Univ Nice Sophia Antipolis | Procede de preparation d'acides et d'esters boroniques en presence de magnesium metallique |
| CA2756870A1 (en) | 2009-03-31 | 2010-10-07 | Arqule, Inc. | Substituted indolo-pyridinone compounds |
| JP5841361B2 (ja) * | 2011-06-29 | 2016-01-13 | 壽製薬株式会社 | 三環性化合物及びそれを含有する医薬組成物 |
| JO3407B1 (ar) | 2012-05-31 | 2019-10-20 | Eisai R&D Man Co Ltd | مركبات رباعي هيدرو بيرازولو بيريميدين |
| AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| US9546162B2 (en) * | 2013-09-27 | 2017-01-17 | Allergan, Inc. | Compounds and methods for skin repair |
| MX382781B (es) | 2014-04-02 | 2025-03-13 | Intermune Inc | Piridinonas anti-fibroticas. |
| GB201810092D0 (en) | 2018-06-20 | 2018-08-08 | Ctxt Pty Ltd | Compounds |
| GB201810581D0 (en) | 2018-06-28 | 2018-08-15 | Ctxt Pty Ltd | Compounds |
| KR102823056B1 (ko) | 2019-06-18 | 2025-06-23 | 화이자 인코포레이티드 | 벤즈이속사졸 설폰아마이드 유도체 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2150113T3 (es) * | 1995-04-03 | 2000-11-16 | Novartis Ag | Derivados de pirazol y procedimientos para la preparacion de los mismos. |
| ZA984040B (en) * | 1997-05-15 | 1998-11-20 | Ono Pharmaceutical Co | Benzenesulfonamide compounds |
| TR200201431T2 (tr) * | 1999-11-30 | 2002-09-23 | Pfizer Products Inc. | İmünosupresanlar olarak faydalı 2,4-diaminopirimidin bileşikleri |
| MXPA04001253A (es) * | 2001-08-09 | 2004-06-03 | Ono Pharmaceutical Co | Derivados de acidos carboxilicos y agente farmaceutico que comprende los mismos como ingrediente activo. |
| JPWO2004078719A1 (ja) * | 2003-03-06 | 2006-06-08 | 小野薬品工業株式会社 | インドール誘導体化合物およびその化合物を有効成分とする薬剤 |
| CA2528626A1 (en) * | 2003-07-09 | 2005-01-20 | Biolipox Ab | Indoles useful in the treatment of inflammation |
| CA2550361C (en) * | 2003-12-19 | 2014-04-29 | Prabha Ibrahim | Compounds and methods for development of ret modulators |
-
2005
- 2005-10-11 US US11/247,456 patent/US20060142348A1/en not_active Abandoned
- 2005-10-11 SG SG200906805-7A patent/SG156637A1/en unknown
- 2005-10-11 RU RU2007115520/04A patent/RU2407736C2/ru not_active IP Right Cessation
- 2005-10-11 MX MX2007004526A patent/MX2007004526A/es unknown
- 2005-10-11 BR BRPI0517417-1A patent/BRPI0517417A/pt not_active IP Right Cessation
- 2005-10-11 JP JP2007536818A patent/JP2008515980A/ja active Pending
- 2005-10-11 CN CNA200580042679XA patent/CN101076529A/zh active Pending
- 2005-10-11 AU AU2005295902A patent/AU2005295902A1/en not_active Abandoned
- 2005-10-11 WO PCT/US2005/036558 patent/WO2006044405A1/en not_active Ceased
- 2005-10-11 EP EP05812269A patent/EP1812426B1/en not_active Expired - Lifetime
- 2005-10-11 AT AT05812269T patent/ATE512144T1/de not_active IP Right Cessation
- 2005-10-11 KR KR1020077010839A patent/KR20070085340A/ko not_active Ceased
- 2005-10-11 NZ NZ554493A patent/NZ554493A/en not_active IP Right Cessation
- 2005-10-11 CA CA002583710A patent/CA2583710A1/en not_active Abandoned
-
2007
- 2007-04-11 IL IL182489A patent/IL182489A0/en unknown
- 2007-05-02 NO NO20072269A patent/NO20072269L/no not_active Application Discontinuation
-
2008
- 2008-11-03 US US12/264,053 patent/US20090075985A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1812426B1 (en) | 2011-06-08 |
| WO2006044405A1 (en) | 2006-04-27 |
| NZ554493A (en) | 2009-09-25 |
| RU2007115520A (ru) | 2008-10-27 |
| US20090075985A1 (en) | 2009-03-19 |
| MX2007004526A (es) | 2007-09-21 |
| EP1812426A1 (en) | 2007-08-01 |
| SG156637A1 (en) | 2009-11-26 |
| NO20072269L (no) | 2007-07-06 |
| BRPI0517417A (pt) | 2008-10-07 |
| RU2407736C2 (ru) | 2010-12-27 |
| AU2005295902A1 (en) | 2006-04-27 |
| JP2008515980A (ja) | 2008-05-15 |
| IL182489A0 (en) | 2007-09-20 |
| CN101076529A (zh) | 2007-11-21 |
| ATE512144T1 (de) | 2011-06-15 |
| CA2583710A1 (en) | 2006-04-27 |
| US20060142348A1 (en) | 2006-06-29 |
| HK1110580A1 (en) | 2008-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20090075985A1 (en) | Aryl sulfonamide peri-substituted bicyclics for occlusive artery disease | |
| ES2325045T3 (es) | Nuevos derivados de pirazol heterociclilmetil sustituidos y su uso en el tratamiento de enfermedades cardiovasculares. | |
| US6787651B2 (en) | Substituted indoles, pharmaceutical compounds containing such indoles and their use as PPAR-γ binding agents | |
| KR101345473B1 (ko) | 헤테로 화합물 | |
| KR102612649B1 (ko) | Pge2 수용체 조절제로서의 벤조푸란 및 벤조티오페논 유도체 | |
| JP6552061B2 (ja) | 代謝型グルタミン酸受容体の負のアロステリックモジュレーター（ｎａｍｓ）とその使用 | |
| US11052092B2 (en) | N-{[2-(piperidin-1-yl)phenyl](phenyl)methyl}-2-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl)acetamide derivatives and related compounds as ROR-gamma modulators for treating autoimmune diseases | |
| WO2008044767A1 (en) | Aromatic amine derivative and use thereof | |
| TW200404060A (en) | Fused heterocyclic compounds | |
| US11970484B2 (en) | LXR modulators with bicyclic core moiety | |
| PT1919869E (pt) | Derivados de indole activadores de ppar | |
| TWI909603B (zh) | 用於預防或治療癌症或腫瘤之新穎化合物及包含該化合物的醫藥組成物 | |
| HK1110580B (en) | Aryl sulfonamide peri-substituted bicyclics for occlusive artery disease | |
| WO2012131031A1 (en) | New positive allosteric modulators of nicotinic acetylcholine receptor | |
| EA045482B1 (ru) | Новые модуляторы lxr с бициклическим центральным фрагментом |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20070511 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| N231 | Notification of change of applicant | ||
| PN2301 | Change of applicant |
Patent event date: 20100121 Comment text: Notification of Change of Applicant Patent event code: PN23011R01D |
|
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20101008 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20120905 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20130325 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20120905 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |